Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

I.S. Nijhof; J.J.L. van Bueren; B. van Kessel; P. Andre; Y. Morel; H.M. Lokhorst; N.W.C.J. van de Donk; P.W.H.I. Parren; T. Mutis

doi:https://doi.org/10.3324/haematol.2014.117531

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

I.S. Nijhof, J.J.L. van Bueren, B. van Kessel, P. Andre, Y. Morel, H.M. Lokhorst, N.W.C.J. van de Donk, P.W.H.I. Parren, T. Mutis

Research output: Contribution to journal › Article › Academic › peer-review

90 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	263-268
Journal	Haematologica
Volume	100
Issue number	2
DOIs	https://doi.org/10.3324/haematol.2014.117531
Publication status	Published - 2015

Access to Document

https://doi.org/10.3324/haematol.2014.117531

Cite this

Nijhof, I. S., van Bueren, J. J. L., van Kessel, B., Andre, P., Morel, Y., Lokhorst, H. M., van de Donk, N. W. C. J., Parren, P. W. H. I., & Mutis, T. (2015). Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica, 100(2), 263-268. https://doi.org/10.3324/haematol.2014.117531

@article{14727911b5f54b609cfdb0ac60d91679,

title = "Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide",

author = "I.S. Nijhof and {van Bueren}, J.J.L. and {van Kessel}, B. and P. Andre and Y. Morel and H.M. Lokhorst and {van de Donk}, N.W.C.J. and P.W.H.I. Parren and T. Mutis",

year = "2015",

doi = "https://doi.org/10.3324/haematol.2014.117531",

language = "Undefined/Unknown",

volume = "100",

pages = "263--268",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "2",

}

TY - JOUR

T1 - Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

AU - Nijhof, I.S.

AU - van Bueren, J.J.L.

AU - van Kessel, B.

AU - Andre, P.

AU - Morel, Y.

AU - Lokhorst, H.M.

AU - van de Donk, N.W.C.J.

AU - Parren, P.W.H.I.

AU - Mutis, T.

PY - 2015

Y1 - 2015

U2 - https://doi.org/10.3324/haematol.2014.117531

DO - https://doi.org/10.3324/haematol.2014.117531

M3 - Article

C2 - 25510242

SN - 0390-6078

VL - 100

SP - 263

EP - 268

JO - Haematologica

JF - Haematologica

IS - 2

ER -